GlassScriptPhysician profile
Cather M Mckay
NPI 1386030617
$7,433.03
in general payments reported to CMS, 2019-2025
27 companies · $1,220 in 2025
The $1,220 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.40 · 2020: $704 · 2021: $1,583 · 2022: $1,185 · 2023: $1,368 · 2024: $1,347 · 2025: $1,220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,748 · Education: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,747.67 |
| Education | $186.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,449.43 | 2020-2025 | |
| Janssen Biotech, INC. | $1,079.41 | 2020-2025 | Tremfya, Simponi Aria, Stelara |
| Regeneron Healthcare Solutions, INC. | $855.02 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $672.83 | 2020-2025 | |
| Amgen INC. | $423.74 | 2020-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $337.47 | 2020-2025 | Blu-U, Absorica Ld, Winlevi |
| Novartis Pharmaceuticals Corporation | $315.12 | 2019-2025 | |
| Leo Pharma INC. | $299.46 | 2020-2025 | Adbry |
| Galderma Laboratories, L.P. | $288.22 | 2021-2025 | Nemluvio |
| Allergan, INC. | $257.91 | 2021 | |
| Lilly USA, LLC | $246.97 | 2020-2024 | Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $179.94 | 2023-2024 | Sotyktu |
| Organogenesis INC. | $179.75 | 2024-2025 | Affinity, Via Matrix |
| Pfizer INC. | $172.82 | 2021-2025 | |
| Incyte Corporation | $112.98 | 2021-2023 | Opzelura |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $105.97 | 2023-2024 | Zoryve |
| Almirall LLC | $89.44 | 2020-2025 | Klisyri, Seysara |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $73.05 | 2021-2023 | Arazlo |
| Sanofi-Aventis U.S. LLC | $64.95 | 2021 | |
| Ucb, INC. | $64.29 | 2020 | |
| Janssen Scientific Affairs, LLC | $43.94 | 2022 | |
| Dermira, INC. | $27.32 | 2020 | |
| Merck Sharp & Dohme LLC | $22.21 | 2023 | Keytruda |
| Helsinn Therapeutics (U.S.), INC. | $21.07 | 2025 | Valchlor |
| Paratek Pharmaceuticals, INC. | $18.94 | 2022 | |
| Stimlabs LLC | $16.67 | 2025 | Allacor P |
| Convatec INC. | $14.11 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cather Mckay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.